Farmers Trust Co. Acquires 3,767 Shares of Kenvue Inc. (NYSE:KVUE)

Farmers Trust Co. increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 217,218 shares of the company’s stock after acquiring an additional 3,767 shares during the period. Farmers Trust Co.’s holdings in Kenvue were worth $4,638,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of KVUE. National Bank of Canada FI increased its position in shares of Kenvue by 23.8% during the 2nd quarter. National Bank of Canada FI now owns 417,999 shares of the company’s stock valued at $7,527,000 after purchasing an additional 80,272 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Kenvue by 54.9% in the 2nd quarter. Victory Capital Management Inc. now owns 799,225 shares of the company’s stock valued at $14,530,000 after acquiring an additional 283,383 shares during the last quarter. Candriam S.C.A. increased its stake in Kenvue by 20.8% in the 2nd quarter. Candriam S.C.A. now owns 85,878 shares of the company’s stock worth $1,561,000 after purchasing an additional 14,784 shares during the period. Acadian Asset Management LLC bought a new stake in Kenvue during the 2nd quarter valued at $412,000. Finally, Caprock Group LLC grew its position in shares of Kenvue by 3.2% in the 2nd quarter. Caprock Group LLC now owns 44,798 shares of the company’s stock worth $814,000 after buying an additional 1,409 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock remained flat at $21.05 on Wednesday. 4,460,462 shares of the stock traded hands, compared to its average volume of 7,644,690. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average price is $22.73 and its 200-day moving average price is $21.56. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a market cap of $40.36 billion, a PE ratio of 38.27, a P/E/G ratio of 2.02 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the firm earned $0.31 EPS. The business’s revenue was down .4% on a year-over-year basis. Research analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.90%. The ex-dividend date was Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the company from $21.00 to $26.00 in a research note on Monday. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Barclays raised Kenvue to a “hold” rating in a report on Thursday, December 12th. Finally, Jefferies Financial Group began coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus price target of $23.09.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.